Business
BELLUS Health announces closing of Innodia acquisition
Company announces change to senior management team ----------------------------------------------...
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nCompany announces change to senior management team\n\n\n--------------------------------------------------\n\n\nLAVAL, QC, July 17 /CNW Telbec/ - BELLUS Health Inc. (NASDAQ: BLUS;\nTSX: BLU, formerly known as Neurochem Inc.) announced today the closing of the\nacquisition of Innodia Inc. that it had previously announced on July 16, 2008.\n\n\nAs a result of this acquisition, BELLUS Health is also announcing a\nchange at the management level in the field of research. Nigel Levens, Ph.D.,\nChief Scientific Officer of Innodia Inc. will take on the position of Vice\nPresident, Research at BELLUS Health while Daniel Delorme, Ph.D., BELLUS\nHealth's current Vice President, Research, will be leaving the Company to\npursue other interests.\n\n\n"I am very pleased to welcome Dr. Levens to the Company," said\nDr. Francesco Bellini, Chairman, President and CEO of BELLUS Health. "The\nexpertise he demonstrated in drug discovery for metabolic diseases at Innodia,\nwill serve us very well at BELLUS Health. I also want to thank Dr. Delorme for\nhis valuable contribution to the Company during his tenure with us and wish\nhim great success in his future endeavours."\n\n\nDr. Levens brings to the position 27 years of teaching and research in\nthe field of metabolic and cardiovascular diseases in both Europe and North\nAmerica. Prior to joining Innodia in 2006, he worked as Head of Biology for\nBiovitrum AB of Sweden, which specializes in metabolic diseases such as\nType II diabetes, obesity, and metabolic syndrome. From 1998-2003, he served\nas Head of the Division of Metabolic Diseases for the Servier Research Group\nin France and prior to that as Head of Obesity Pharmacology for Novartis\nPharma in Basel, Switzerland. Educated in both the United Kingdom and the\nUnited States, Dr. Levens holds a B.Sc. (Hons.) in Physiology and\nBiochemistry, and a Ph.D. in Physiology from the University of Southampton in\nthe United Kingdom and conducted a postdoctoral fellowship in pharmacology at\nthe University of Virginia.\n\n\nAbout BELLUS Health\n\n\nBELLUS Health is a global health company focused on the development and\ncommercialization of products to provide innovative health solutions to\naddress critical unmet medical needs.\n\n\nTo Contact BELLUS Health\n\n\nFor additional information on BELLUS Health and its programs, p...